Copy to clipboard 
Medartis reported 2H21 orthopedic sales of CHF 86.3 million (USD $97.5 million), +22.2% vs. 2H20. For the full year, the company generated CHF 159.9 million (USD $180.7 million) in orthopedic sales, +25.3% vs. the year prior.
The company turned in strong performances across the board, growing more than +20% in each of its product categories and sales regions for the full year. Medartis’ late-2020 investment in KeriMedical helped drive strong upper extremity performance in Germany and Austria.
Medartis doubled down on its investment in the U.S. market with the acquisition of Nextremity Solutions in the first quarter of 2022. The deal gives Medartis a dedicated lower extremity franchise in the U.S., and is expected to generate an additional $150 million in orthopedic sales by 2028. The company plans to support the acquisition through significant investment in Medartis’ U.S. commercial organization.
According to Medartis, hospital capacity reached approximately 90% of its normal volume by the end of 2021. The company expects organic sales growth of +20% in 2022.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 2H21 | 2H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Trauma | $81.9 | $68.9 | $13.0 | 18.9% |
| Other (CMF) | $15.6 | $10.8 | $4.7 | 43.8% |
| Total | $97.5 | $79.8 | $17.7 | 22.2% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Trauma | $154.5 | $125.0 | $29.5 | 23.6% |
| Other (CMF) | $26.2 | $19.2 | $7.0 | 36.5% |
| Total | $180.7 | $144.2 | $36.5 | 25.3% |
Orthopedic Sales by Geography
| 2H21 | 2H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $20.3 | $17.2 | $3.2 | 18.4% |
| OUS | $77.2 | $62.6 | $14.6 | 23.3% |
| EMEA | $49.5 | $40.7 | $8.8 | 21.7% |
| APAC | $18.8 | $16.5 | $2.3 | 13.7% |
| ROW | $8.9 | $5.4 | $3.5 | 64.6% |
| Total | $97.5 | $79.8 | $17.7 | 22.2% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $34.8 | $27.7 | $7.1 | 25.7% |
| OUS | $145.9 | $116.5 | $29.4 | 25.2% |
| EMEA | $94.2 | $76.8 | $17.4 | 22.6% |
| APAC | $36.2 | $28.7 | $7.5 | 26% |
| ROW | $15.5 | $11.0 | $4.5 | 41.2% |
| Total | $180.7 | $144.2 | $36.5 | 25.3% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Medartis reported 2H21 orthopedic sales of CHF 86.3 million (USD $97.5 million), +22.2% vs. 2H20. For the full year, the company generated CHF 159.9 million (USD $180.7 million) in orthopedic sales, +25.3% vs. the year prior.
The company turned in strong performances across the board, growing more than +20% in each of its product categories...
Medartis reported 2H21 orthopedic sales of CHF 86.3 million (USD $97.5 million), +22.2% vs. 2H20. For the full year, the company generated CHF 159.9 million (USD $180.7 million) in orthopedic sales, +25.3% vs. the year prior.
The company turned in strong performances across the board, growing more than +20% in each of its product categories and sales regions for the full year. Medartis’ late-2020 investment in KeriMedical helped drive strong upper extremity performance in Germany and Austria.
Medartis doubled down on its investment in the U.S. market with the acquisition of Nextremity Solutions in the first quarter of 2022. The deal gives Medartis a dedicated lower extremity franchise in the U.S., and is expected to generate an additional $150 million in orthopedic sales by 2028. The company plans to support the acquisition through significant investment in Medartis’ U.S. commercial organization.
According to Medartis, hospital capacity reached approximately 90% of its normal volume by the end of 2021. The company expects organic sales growth of +20% in 2022.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 2H21 | 2H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Trauma | $81.9 | $68.9 | $13.0 | 18.9% |
| Other (CMF) | $15.6 | $10.8 | $4.7 | 43.8% |
| Total | $97.5 | $79.8 | $17.7 | 22.2% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Trauma | $154.5 | $125.0 | $29.5 | 23.6% |
| Other (CMF) | $26.2 | $19.2 | $7.0 | 36.5% |
| Total | $180.7 | $144.2 | $36.5 | 25.3% |
Orthopedic Sales by Geography
| 2H21 | 2H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $20.3 | $17.2 | $3.2 | 18.4% |
| OUS | $77.2 | $62.6 | $14.6 | 23.3% |
| EMEA | $49.5 | $40.7 | $8.8 | 21.7% |
| APAC | $18.8 | $16.5 | $2.3 | 13.7% |
| ROW | $8.9 | $5.4 | $3.5 | 64.6% |
| Total | $97.5 | $79.8 | $17.7 | 22.2% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $34.8 | $27.7 | $7.1 | 25.7% |
| OUS | $145.9 | $116.5 | $29.4 | 25.2% |
| EMEA | $94.2 | $76.8 | $17.4 | 22.6% |
| APAC | $36.2 | $28.7 | $7.5 | 26% |
| ROW | $15.5 | $11.0 | $4.5 | 41.2% |
| Total | $180.7 | $144.2 | $36.5 | 25.3% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
